On May 29, 2020, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Tecentriq (atezolizumab). This approval, categorized under efficacy, signifies an expansion of the drug's approved uses, based on new data submitted by the sponsor, Genentech Inc.
Background
Atezolizumab, marketed under the brand name Tecentriq, is an established therapeutic agent that had previously received FDA approval for various indications. A supplemental application for efficacy, such as this one, typically indicates that new clinical data has demonstrated the drug's effectiveness for an additional use, a new patient population, or an expanded scope within its existing indications. These approvals are crucial for extending the reach of established therapies to more patients who could benefit from their therapeutic effects, reinforcing the drug's overall value in clinical practice.
What this means
This supplemental approval for Tecentriq (atezolizumab) signifies an expansion of its approved therapeutic utility. For clinicians, this means that atezolizumab is now indicated for an additional or expanded patient population, or a new specific condition, where its efficacy has been formally recognized by the FDA. This development provides healthcare providers with more options for patients who may benefit from atezolizumab's established therapeutic profile. Patient advocates and researchers will note this as a positive step in making effective treatments available to a broader range of individuals, further solidifying atezolizumab's role in clinical practice by broadening its application based on new efficacy data.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for supplemental application BLA 761034 S-25 for Tecentriq (atezolizumab) was recorded on May 29, 2020, and is accessible via accessdata.fda.gov.